Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Clumeck

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Journal of Human Virology|April 9, 1999
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparationsP Hermans, N Clumeck, O Picard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infectionJulio Montaner, Patrick Yeni, Nathan N Clumeck, et al.
Journal of Clinical Epidemiology|November 1, 1996
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study GroupA N Phillips, A Lazzarin, J Gonzales-Lahoz, et al.
AIDS (London, England)|March 15, 1997
Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study GroupP Hermans, J Lundgren, B Sommereijns, et al.
European Journal of Epidemiology|March 1, 1987
Seroepidemiological study on sexually transmitted diseases and hepatitis B in African promiscuous heterosexuals in relation to HTLV-III infectionP Van de Perre, N Clumeck, M Steens, et al.
The New England Journal of Medicine|August 17, 1995
A controlled trial of zidovudine in primary human immunodeficiency virus infectionS Kinloch-De Loës, B J Hirschel, B Hoen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in EuropeG Moyle, A Pozniak, M Opravil, et al.
The Journal of Infectious Diseases|August 19, 2000
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infectionD Smith, M M Berrey, M Robertson, et al.
The New England Journal of Medicine|July 29, 1993
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative GroupD A Cooper, J M Gatell, S Kroon, et al.
Lancet (London, England)|September 7, 1985
Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type IIIP Van de Perre, N Clumeck, M Carael, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Journal of Human Virology|April 9, 1999
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparationsP Hermans, N Clumeck, O Picard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infectionJulio Montaner, Patrick Yeni, Nathan N Clumeck, et al.
Journal of Clinical Epidemiology|November 1, 1996
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study GroupA N Phillips, A Lazzarin, J Gonzales-Lahoz, et al.
AIDS (London, England)|March 15, 1997
Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study GroupP Hermans, J Lundgren, B Sommereijns, et al.
European Journal of Epidemiology|March 1, 1987
Seroepidemiological study on sexually transmitted diseases and hepatitis B in African promiscuous heterosexuals in relation to HTLV-III infectionP Van de Perre, N Clumeck, M Steens, et al.
The New England Journal of Medicine|August 17, 1995
A controlled trial of zidovudine in primary human immunodeficiency virus infectionS Kinloch-De Loës, B J Hirschel, B Hoen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in EuropeG Moyle, A Pozniak, M Opravil, et al.
The Journal of Infectious Diseases|August 19, 2000
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infectionD Smith, M M Berrey, M Robertson, et al.
The New England Journal of Medicine|July 29, 1993
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative GroupD A Cooper, J M Gatell, S Kroon, et al.
Lancet (London, England)|September 7, 1985
Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type IIIP Van de Perre, N Clumeck, M Carael, et al.
Pageof 20